SS
RKDA icon

Steve Schonfeld’s Arcadia Biosciences RKDA Stock Holding History

Steve Schonfeld’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-325
Closed -$27K – 2472
2021
Q3 		$27K Sell
325
-63
-16% -$5.91K ﹤0.01% 2035
2021
Q2 		$46K Buy
+388
New +$42.3K ﹤0.01% 1876

Other funds holding RKDA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Steve Schonfeld's RKDA Position: Q4 2021 in Review

Steve Schonfeld sold out of Arcadia Biosciences (RKDA) in Q4 2021, closing a stake of 325 shares — an estimated $27K sold.

Steve Schonfeld first reported a position in RKDA in Q2 2021 and held it in 2 quarters. The position peaked at $46K in Q2 2021. 27 funds tracked by Wall St. Rank hold RKDA as of Q4 2021.

  • Steve Schonfeld reported no remaining Arcadia Biosciences position as of Q4 2021 after selling out during the quarter.
  • Steve Schonfeld sold 325 Arcadia Biosciences shares in Q4 2021, an estimated $27K.
  • Steve Schonfeld first reported a position in Arcadia Biosciences in Q2 2021 and held it in 2 quarters.
  • Steve Schonfeld's Arcadia Biosciences position peaked at $46K in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.